# Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma

> **NCT00119730** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 30 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Mitoxantrone
- **DRUG:** Rituximab
- **DRUG:** Zevalin

## Key facts

- **NCT ID:** NCT00119730
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2006-12
- **Final completion:** 2013-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2014-04-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00119730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00119730, "Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00119730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*